Eagle Pharmaceuticals (EGRX) vs. Its Competitors Head-To-Head Comparison
Eagle Pharmaceuticals (NASDAQ: EGRX) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Eagle Pharmaceuticals to related companies based on the strength of its dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
This table compares Eagle Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eagle Pharmaceuticals Competitors||-538.85%||-41.85%||-24.81%|
Earnings & Valuation
This table compares Eagle Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Eagle Pharmaceuticals||$245.88 million||$83.99 million||10.10|
|Eagle Pharmaceuticals Competitors||$2.40 billion||$905.93 million||3.52|
Eagle Pharmaceuticals’ competitors have higher revenue and earnings than Eagle Pharmaceuticals. Eagle Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
66.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 19.5% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Eagle Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eagle Pharmaceuticals Competitors||98||367||965||28||2.63|
Eagle Pharmaceuticals currently has a consensus target price of $72.50, indicating a potential upside of 20.61%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 25.59%. Given Eagle Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Eagle Pharmaceuticals has less favorable growth aspects than its competitors.
Volatility & Risk
Eagle Pharmaceuticals has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals’ competitors have a beta of 0.81, indicating that their average stock price is 19% less volatile than the S&P 500.
Eagle Pharmaceuticals beats its competitors on 7 of the 13 factors compared.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.